Vesey Street

Hercules Capital Prices Upsized Public Offering of $350.0 Million 3.375% Notes due 2027

Retrieved on: 
Friday, January 14, 2022 - 10:33pm

Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), today announced that it has priced an underwritten public offering of $350.0 million in aggregate principal amount of 3.375% notes due January 2027 (the Notes).

Key Points: 
  • Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), today announced that it has priced an underwritten public offering of $350.0 million in aggregate principal amount of 3.375% notes due January 2027 (the Notes).
  • The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on January 20, 2022.
  • Goldman Sachs & Co. LLC, RBC Capital Markets, LLC, and SMBC Nikko Securities America, Inc. are acting as joint book-running managers of this offering.
  • In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY).

Ares Capital Corporation Prices Public Offering

Retrieved on: 
Thursday, January 13, 2022 - 2:15am

Ares Capital Corporation (Nasdaq: ARCC) announced that it has priced a public offering of 10,000,000 shares of its common stock.

Key Points: 
  • Ares Capital Corporation (Nasdaq: ARCC) announced that it has priced a public offering of 10,000,000 shares of its common stock.
  • Ares Capital expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its credit facilities.
  • Ares Capital believes its loans and other investments in these companies can generate attractive levels of current income and potential capital appreciation for investors.
  • Ares Capital is externally managed by a subsidiary of Ares Management Corporation (NYSE: ARES), a publicly traded, leading global alternative investment manager.

Andretti Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering

Retrieved on: 
Wednesday, January 12, 2022 - 11:30pm

Andretti Acquisition Corp., a special purpose acquisition company (the Company), announced today the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit.

Key Points: 
  • Andretti Acquisition Corp., a special purpose acquisition company (the Company), announced today the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit.
  • The offering is expected to close on January 18, 2022, subject to customary closing conditions.
  • The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.
  • No assurance can be given that the proposed initial public offering will be completed on the terms described, or at all, or that the net proceeds of the initial public offering will be used as indicated.

Ares Capital Corporation Announces Public Offering

Retrieved on: 
Wednesday, January 12, 2022 - 9:09pm

Ares Capital Corporation (Nasdaq: ARCC) announced that it plans to make a public offering of 10,000,000 shares of its common stock.

Key Points: 
  • Ares Capital Corporation (Nasdaq: ARCC) announced that it plans to make a public offering of 10,000,000 shares of its common stock.
  • Ares Capital expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its debt facilities.
  • Ares Capital believes its loans and other investments in these companies can generate attractive levels of current income and potential capital appreciation for investors.
  • Ares Capital is externally managed by a subsidiary of Ares Management Corporation (NYSE: ARES), a publicly traded, leading global alternative investment manager.

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, January 7, 2022 - 9:01pm

In addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares.

Key Points: 
  • In addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares.
  • All of the shares in the offering were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $460.0 million and net proceeds of approximately $433.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • J.P. Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets acted as joint book-running managers for the offering.
  • The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

Intra-Cellular Therapies Prices Public Offering of Common Stock

Retrieved on: 
Wednesday, January 5, 2022 - 3:05am

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.

Key Points: 
  • NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.
  • All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses.
  • J.P. Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets are acting as joint book-running managers for the offering.
  • Forward-looking statements include statements, other than statements of historical fact, regarding, among other things, the completion and timing of the public offering and the anticipated total gross proceeds from the offering.

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, January 3, 2022 - 9:01pm

In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.

Key Points: 
  • In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
  • All of the shares in the offering will be sold by Intra-Cellular Therapies.
  • J.P. Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets are acting as joint book-running managers for the offering.
  • Forward-looking statements include statements, other than statements of historical fact, regarding, among other things, the proposed public offering of common stock.

BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States

Retrieved on: 
Friday, December 17, 2021 - 2:30pm

BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the Company or BELLUS Health) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the Offering) of 25,000,000 common shares at a price to the public of US$8.00 per common share.

Key Points: 
  • BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the Company or BELLUS Health) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the Offering) of 25,000,000 common shares at a price to the public of US$8.00 per common share.
  • The total gross proceeds to the Company were US$200 million, before deducting the underwriting commissions and any expenses related to the Offering.
  • BELLUS Healths common shares are dual-listed on the Nasdaq Global Market (Nasdaq) and the Toronto Stock Exchange (TSX) under the trading symbol BLU.
  • BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders.

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

Retrieved on: 
Wednesday, December 15, 2021 - 2:25am

The shares are being sold at a public offering price of US$8.00 per common share.

Key Points: 
  • The shares are being sold at a public offering price of US$8.00 per common share.
  • Closing of the Offering is expected to occur on December 17, 2021, subject to the satisfaction of customary closing conditions.
  • BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders.
  • BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct.

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

Retrieved on: 
Monday, December 13, 2021 - 9:01pm

The Supplement and the accompanying Base Prospectus contain important detailed information about the Offering. The Supplement and the accompanying Base Prospectus can be found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from the Company, by telephone at 450-­‐680-­‐4500 or by email at info@bellushealth.com or you may request them from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877--821--7388 or by email at prospectus_department@jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets , 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at 888-474-0200 or by email at ecm.prospectus@evercore.com; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, New York 10281, by telephone at (877) 822-4089 or by email at equityprospectus@rbccm.com. Prospective investors should read the Supplement and accompanying Base Prospectus and the other documents the Company has filed before making an investment decision.

Key Points: 
  • The Company also expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the Offering.
  • The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing.
  • There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
  • The closing of the Offering will be subject to customary closing conditions including approval from the TSX.